Egyptian International Pharmaceutical Investments (CAI:PHAR) EBIT : E£2,320 Mil (TTM As of Sep. 2024)

View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments EBIT?

Egyptian International Pharmaceutical Investments's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was E£590 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was E£2,320 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Egyptian International Pharmaceutical Investments's annualized ROC % for the quarter that ended in Sep. 2024 was 11.13%. Egyptian International Pharmaceutical Investments's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 23.13%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Egyptian International Pharmaceutical Investments's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 15.57%.

Egyptian International Pharmaceutical Investments EBIT Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments EBIT Chart

Egyptian International Pharmaceutical Investments Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

704.87

790.42

1,000.17

1,471.78

Egyptian International Pharmaceutical Investments Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial															302.05	353.26	817.36	558.89	590.00

Competitive Comparison of Egyptian International Pharmaceutical Investments's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Egyptian International Pharmaceutical Investments's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Egyptian International Pharmaceutical Investments's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Egyptian International Pharmaceutical Investments's EV-to-EBIT falls into.

Egyptian International Pharmaceutical Investments EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was E£2,320 Mil.

Egyptian International Pharmaceutical Investments (CAI:PHAR) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Egyptian International Pharmaceutical Investments's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	2082.316 * ( 1 - 33.46% )	/	( (11988.009	+	12915.573)	/ 2 )
=	1385.5730664	/	12451.791
=	11.13 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	13901.658	-	730.36	-	( 1183.289	-	max(0, 4658.721	-	7670.636	+	1183.289	))
=	11988.009

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	14704.193	-	665.985	-	( 1122.635	-	max(0, 5223.718	-	8167.703	+	1122.635	))
=	12915.573

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Egyptian International Pharmaceutical Investments's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	2360.016	/	( ( (5784.414 + max(4179.118, 0))	+	(6049.1 + max(4398.117, 0)) )	/	2 )
=	2360.016	/	( ( 9963.532	+	10447.217 )	/	2 )
=	2360.016	/	10205.3745
=	23.13 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1984.696	+	3128.306	+	118.642)	-	(730.36	+	0	+	322.166)
=	4179.118

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1839.396	+	3450.815	+	157.759)	-	(665.985	+	0	+	383.868)
=	4398.117

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Egyptian International Pharmaceutical Investments's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	2319.515	/	14895.873
	=	15.57 %

Egyptian International Pharmaceutical Investments EBIT Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Egyptian International Pharmaceutical Investments Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

1st Industrial Zone B1, P.O. Box 149 10th, 10th of Ramadan, EGY

Website

http://www.eipico.com.eg

Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.